Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9792
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJefford, Michaelen
dc.contributor.authorKiffer, John Den
dc.contributor.authorSomers, Ginoen
dc.contributor.authorDaniel, Freddy Jen
dc.contributor.authorDavis, Ian Den
dc.date.accessioned2015-05-15T23:01:58Z
dc.date.available2015-05-15T23:01:58Z
dc.date.issued2004-08-01en
dc.identifier.citationANZ Journal of Surgery; 74(8): 704-5en
dc.identifier.govdoc15315581en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/9792en
dc.description.abstractBasal cell carcinoma (BCC) is the most common cancer in the community, although it rarely metastasizes. The literature reports less than 100 patients who have received chemotherapy for metastatic BCC. A further case of this rare disease is reported here. The pattern of disease in the reported patient was similar to that described in the literature, but the patient experienced a long period with untreated metastatic disease compared with that in the literature.The patient was treated with cisplatin in combination with paclitaxel. Literature review suggests this to be the first report of this combination.Rapid symptomatic response was achieved though late neurotoxicity occurred.This regimen is an active combination for the rare patient with metastatic BCC. The combination of carboplatin and paclitaxel causes less neurotoxicity and may therefore be a superior regimen.en
dc.language.isoenen
dc.subject.otherAntineoplastic Agents.therapeutic useen
dc.subject.otherCarcinoma, Basal Cell.drug therapy.secondaryen
dc.subject.otherCisplatin.therapeutic useen
dc.subject.otherHumansen
dc.subject.otherLung Neoplasms.drug therapy.secondaryen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherPaclitaxel.therapeutic useen
dc.subject.otherRemission Inductionen
dc.subject.otherSkin Neoplasms.pathologyen
dc.subject.otherTime Factorsen
dc.titleMetastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel.en
dc.typeJournal Articleen
dc.identifier.journaltitleANZ Journal of Surgeryen
dc.identifier.affiliationmichael.jefford@petermac.orgen
dc.identifier.affiliationLudwig Institute for Cancer Research, Austin and Repatriation Medical Centre, Victoria, Australiaen
dc.identifier.doi10.1111/j.1445-1433.2004.03130.xen
dc.description.pages704-5en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/15315581en
dc.type.austinJournal Articleen
item.cerifentitytypePublications-
item.languageiso639-1en-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

6
checked on Feb 3, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.